18 results about "Epithelial cell adhesion molecule" patented technology

The present invention provides a DNA-Pb 2+ The present invention relates to a homogeneous electrochemical analysis method and application of functional nano-hydrogel for exosome detection, which relates to the technical field of biomedical diagnostic analysis methods. The present invention is based on the DNA nano-hydrogel prepared by the rolling circle amplification (RCA) method, combining the G-quadruplex structure with Pb 2+ The specific recognition mechanism was constructed, and the epithelial cell adhesion molecule (EpCAM) on the surface of exosomes was selected as the detection target. The specific binding between EpCAM and its aptamer triggered the disintegration of DNA nanohydrogel, thereby exposing a large number of G-quadruplex structures generated by RCA, which could bind to Pb 2+ By selectively binding and regulating the electrochemical signal output, this method realizes a one-pot, rapid and efficient detection process, and the entire process is completed within 45 minutes.

The present invention generally relates to a medium composition and method for culturing mesenchymal stem cells (MSCs), in which the medium comprises an epithelial cell adhesion molecule (EpCAM) peptide, particularly a truncated EpCAM polypeptide containing the extracellular domain (EpEX). It significantly enhances cell proliferation and multipotency of the MSCs.

A modified cell is provided that expresses (a) a chimeric antigen receptor targeting GPC3 and / or CD19, and (b) a multispecific antigen binding protein, variant or binding fragment thereof that binds to one or more targets, comprising a first antigen binding protein, variant or binding fragment thereof that binds to EpCAM (epithelial cell adhesion molecule), and a second antigen binding protein, variant or binding fragment thereof, which binds to an immune cell marker, wherein the first antigen binding protein, variant or binding fragment thereof, which binds to EpCAM comprises a heavy chain variable region and / or a light chain variable region comprising a sequence as disclosed herein. Also disclosed are methods of generating / generating cells as disclosed herein and methods of treating with cells as disclosed herein.

The invention provides a method for detecting PD-L1 expression in circulating tumor cells, and belongs to the technical field of bioinformation.The method comprises the steps that peripheral blood samples are collected from at least 100 groups of patients, the circulating tumor cells are separated through density gradient centrifugation, specific labeling is carried out through anti-epithelial cell adhesion molecule antibodies and anti-PD-L1 fluorescence labeling antibodies, and then the peripheral blood samples are subjected to fluorescence labeling; then, a flow cytometer is used for obtaining multi-dimensional fluorescence signals for quantitative analysis, and a multi-dimensional characteristic data set containing time characteristics, intensity characteristics and spatial distribution characteristics is constructed; based on the historical data, a multi-head attention enhanced adversarial generative network model containing eight independent attention heads is constructed and trained, key hyper-parameters in the training process are dynamically adjusted through a parameter optimization function, and finally the expression level of the circulating tumor cells PD-L1 in a to-be-detected sample is quantitatively analyzed by applying the trained model. The high-precision detection of the expression of the circulating tumor cells PD-L1 is realized.

The disclosure relates to peptide conjugates specific for Epithelial cell adhesion molecule (EpCAM) and the use thereof to detect and treat epithelial cell-derived cancers such as intrahepatic cholangiocarcinoma (ICC), hepatocellular carcinoma (HCC), breast cancer, colon cancer and basal cell carcinoma of the skin. The disclosure also relates to methods to monitor the therapeutic response of treated patients by detecting expression of EpCAM.

The present invention relates to antigen binding proteins specific for epithelial cell adhesion molecules (EpCAM), variants and fragments thereof, as well as multispecific antigen binding proteins that bind to EpCAM and other targets, such as bispecific T cell conjugates (BiTE). The invention also provides compositions comprising the antigen binding proteins, variants and fragments thereof, cells expressing / secreting them, methods of treatment employing the antigen binding proteins, variants and fragments thereof, and other uses thereof. In one embodiment, the cell is an immune cell, e.g., selected from the group consisting of T cells, macrophages, monocytes, and NK cells. In more specific embodiments, the cells are CAR T cells.

The invention relates to a nucleic acid construct, comprising: a first nucleic acid sequence region encoding a dual chimeric antigen receptor (CAR) polypeptide, said dual CAR polypeptide comprising a first extracellular antigen-binding domain that binds an epithelial cell adhesion molecule (EpCAM), and a second extracellular antigen-binding domain of the dual CAR that binds a carcinoembryonic antigen (CEA) protein, and a second nucleic acid sequence region encoding an immune stimulatory cytokine. The invention further relates to a dual chimeric antigen receptor (CAR) polypeptide encoded by the nucleic acid construct. The invention further relates to a genetically modified cell, comprising said nucleic acid construct and / or said dual CAR, the medical use of said cells in the treatment of a medical disorder associated with the presence of pathogenic cells expressing CEA and / or EpCAM in a subject and a pharmaceutical composition, in the form of a therapeutic cell product, comprising said genetically modified cells and a pharmaceutically acceptable carrier. Further, the invention relates to an in vitro method for preparing said genetically modified immune cell, comprising delivering said nucleic acid construct into a cell.

The present invention relates to an anti-epithelial cell adhesion molecule (anti-EpCAM) monoclonal antibody and use thereof. In the anti-EpCAM antibody of the present invention, a biopanning technique using an OPAL library having a diversity of 1×1010 was used, and a group of anti-EpCAM therapeutic antibody candidates was selected through an enzyme-linked immunosorbent assay. FACS verification was performed to confirm the binding of anti-EpCAM candidate antibodies, and the binding affinity of the candidate antibodies in tumor tissues was confirmed through IHC. In addition, the affinity of the candidate antibodies was verified through surface plasmon response analysis. For the two types of candidate antibodies verified above, the potential thereof as ADCs was evaluated, and the spheroid formation inhibitory activity of the candidate antibodies was verified to confirm the degree of inhibition of cancer cell proliferation induction. As a result of evaluating the anticancer efficacy of the candidate antibodies in an orthotropic colon cancer mice model, the candidate antibodies exhibited an excellent anticancer effect. Therefore, the antibodies produced in the present invention are likely to be effectively used as antibody therapeutic agents having an anticancer effect.

The present disclosure relates to multimers of a phosphatidylinositol-3 (GPC3)-specific peptide, a CD44-specific peptide, and an epithelial cell adhesion molecule (EpCAM)-specific peptide, and their use for the detection and treatment of epithelial cell-derived cancers, the epithelial cell-derived cancers such as hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), breast cancer, colon cancer, gastric cancer, ovarian cancer, cervical cancer, and skin basal cell carcinoma. The present disclosure also relates to methods for monitoring the therapeutic response of a treated patient using the peptide multimers.

Abstract A method for detecting a biological marker in a sample, preferably a biological marker on a cancer cell, the method comprising: (i) contacting the sample with at least one DNA aptamer coupled to a first reagent and wherein the aptamer specifically binds to a first biological marker in the sample to form a first complex; (ii) contacting the first complex of (i) with a second binding agent that specifically binds to the first reagent such that a second complex is formed, wherein the second binding agent is coupled to a reporter molecule; (iii) contacting the second complex (ii) with a substrate for the reporter molecule of the at least one second binding agent; and (iv) detecting the substrate reaction by formation of a reaction product thereby detecting the biological marker in the sample. Biological markers include cytokeratin 8 (CK8), cytokeratin 18 (CK18), human epidermal growth factor receptor 2 (HER2) and epithelial cell adhesion molecule (EpCAM). Abstract 41 / 50 FIGURE 40 Frozen section preparation 4 Sample fixation + Wash (10 dips in PBS) DNA aptamer staining DAB Substrate DAB substrate HRP FAM Anti-FITC conjugated with HRP FAM DNA Aptamer conjugated with FAM HRP Frozen section slide / Touch imprint slide / Cytology slide / Direct smear slide Anti-FITC-HRP Wash (10 dips in PBS) DAB Wash (10 dips in PBS) Hematoxylin counter-staining Wash under tap water Cove rs lip DAB brown precipitate at the location of the aptamer B o min 1 min 15 sec 5 min 15 sec 5 min 15 sec 5 min 15 sec 10 sec 1 min 1 min A + Wash (10 dips in PBS) Total time for aptamer-DAB staining: —18 min 4 1 / 5 0 A B 1 0 m i n 1 m i n D A B s u b s t r a t e 1 5 s e c H R P A n t i - F I T C 5 m i n D N A a p t a m e r s t a i n i n g H R P 1 5 s e c 5 m i n 1 5 s e c D N A A p t a m e r c o n j u g a t e d w i t h F A M 5 m i n D A B W a s h ( 1 0 d i p s i n P B S ) F r o z e n s e c t i o n s l i d e / T o u c h i m p r i n t s l i d e / C y t o l o g y s l i d e / D i r e c t s m e a r s l i d e c o u n t e r - s t a i n i n g 1 m i n W a s h u n d e r t a p w a t e r 1 m i n C o v e r s l i p F I G U R E 4 020 25 28 36 33 19 D ec 2 02 5 1 9 D e c 2 0 2 5 A B 1 0 m i n F r o z e n s e c t i o n p r e p a r a t i o n 1 m i n S a m p l e f i x a t i o n D A B 2 0 2 5 2 8 3 6 3 3 s u b s t r a t e 1 5 s e c W a s h ( 1 0 d i p s i n P B S ) H R P A n t i - F I T C 5 m i n D N A a p t a m e r s t a i n i n g H R P 1 5 s e c 5 m i n A n t i - F I T C - H R P T o t a l t i m e f o r 1 5 s e c D N A A p t a m e r W a s h ( 1 0 d i p s i n P B S ) c o n j u g a t e d w i t h F A M 5 m i n D A B s t a i n i n g : ~ 1 8 m i n W a s h ( 1 0 d i p s i n P B S ) F r o z e n s e c t i o n s l i d e / T o u c h i m p r i n t s l i d e / 1 0 s e c H e m a t o x y l i n C y t o l o g y s l i d e / D i r e c t s m e a r s l i d e c o u n t e r - s t a i n i n g 1 m i n W a s h u n d e r t a p w a t e r 1 m i n C o v e r s l i p F I G U R E 4 0

The disclosure relates to multimers of Glypican-3 (GPC3)-, CD44-, and Epithelial cell adhesion molecule (EpCAM)-specific peptides and the use thereof to detect and treat epithelial cell-derived cancers such as hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), breast cancer, colon cancer, gastric cancer, ovarian cancer, cervical cancer, and basal cell carcinoma of the skin. The disclosure also relates to methods to monitor the therapeutic response of treated patients using the peptide multimers.

The application belongs to the technical field of biology and relates to a biomarker for early diagnosis of non-small cell lung cancer and application thereof. The biomarker comprises a combination of secreted phosphoprotein 1, epithelial cell adhesion molecule and matrix metallopeptidase 14, and / or a combination of a coding nucleic acid of secreted phosphoprotein 1, a coding nucleic acid of epithelial cell adhesion molecule and a coding nucleic acid of matrix metallopeptidase 14; the coding nucleic acid comprises mRNA or cDNA. A non-small cell lung cancer circulating tumor cell score diagnosis model constructed by taking the biomarker as a feature has a diagnosis accuracy of 87.5% in a test set, and the sensitivity and specificity are 92.5% and 82.5% respectively. Compared with existing tumor indexes in the clinic, the biomarker can detect cancer at an earlier stage and is conducive to early screening of non-small cell lung cancer.

The application discloses a tumor marker for colorectal cancer diagnosis and a nucleic acid aptamer-based detection method, relates to a nucleic acid aptamer sequence for specifically recognizing epithelial cell adhesion molecule (EpCAM) and prion protein (PRNP), EpCAM and PRNP proteins as colorectal cancer diagnosis markers and a method for detecting expression levels in exosomes. The nucleic acid aptamer sequence is obtained by screening a cell-SELEX (systematic evolution of ligands by exponential enrichment) technology with colorectal cancer cells as targets, can be chemically synthesized in vitro, is stable in structure, easy to modify and replace, low in cost and high in reproducibility; and the target protein is highly enriched in exosomes derived from colorectal cancer tumor cells and can be used as a colorectal cancer diagnosis marker. The nucleic acid aptamer obtained by the application can be applied to imaging of human colorectal cancer related malignant tumor cells and derived exosomes, preparation of coupled drugs, clinical diagnosis and development of related kits.

The present invention relates to combined therapy of cancer using an epithelial cell adhesion molecule (EpCAM) inhibitor and a hepatocyte growth factor receptor (HGFR) inhibitor. Specifically, the EpCAM inhibitor is an antibody which is directed to an extracellular domain (EpEX) of EpCAM. The combined therapy is effective in inducing apoptosis of cancer cells, inhibiting migration / invasion of cancer cells, reducing tumor size, and / or prolonging survival of a cancer patient.

A portable device for early cancer tumor detecting using the advantages of Ep-CAM antigen properties (Epithelial Cell Adhesion Molecule) which adhere to cancer cells and ability to adhere SPIONs. In this invention we calculate the concentration of ferric ions which have to adhere to the cancer cells throw the antigen. We add the antigen mixed with SPIONs to a blood sample and enriches, incubate and then inject it into the device to process it and produce a residual for test. A special Test strip designed for this device consists of two reagents potassium ferrocyanide and potassium thiocyanate. The purpose of using two -reagents test strip is to increase the integrity of the test. If the sample contain cancer tumor cells, then the antigen will stick to this cell with the ferric ions and the device contain a removable filter unit with a micro pore size to prevent tumor cells from passing throw it. If the sample contain cancer cell, the all-ferric ions will stick to it and not passing through the filter. The residual will not contain any ferric ions and the test strip will act nothing. If the sample is free of cancer cell, then the antigen will find nothing to stick with and consequently the ferric ions which will pass through the filter to precipitate in the residual. The test strip will change color according to reaction with ferric ions which is indication of free-cancer sample.

Herein is provided a novel molecule and infusion solutions containing the molecule useful for the detection and imaging of EpCAM positive tumors as well as lymph nodes, such as, but not limited to, lower GI (i.e. colorectal) and upper GI (i.e. gastric and esophageal) cancers. The molecule is comprised of an antibody or antibody fragment capable of specifically targeting EpCAM conjugated to a NIR fluorescent dye. A preferred antibody fragment is VB5-845D and a preferred NIR fluorescent dye is IRDye 800CW. Aspects of the invention provide a method of intraoperative tumor visualization of EpCAM expressing primary tumors and lymph nodes.

Fibroblast activation protein a (FAP) is a tumor-specific protein and well characterized for its function in tumorigenicity. However, agents against its enzymatic activity or monoclonal antibodies against its cell surface presence are unsuccessful in clinic for uncharacterized reason. In this disclosure, provided is an anti-FAP siRNA and FAP-silencing oligonucleotides comprising anti-FAP siRNAs linked at both ends to aptamers recognizing cancer markers, in particular aptamers recognizing epithelial cell adhesion molecule (EpCAM).

Modified cells are provided that express (a) a chimeric antigen receptor targeting HER2, and (b) a multispecific antigen binding protein, variant or binding fragment thereof that binds to one or more targets, the present invention relates to antigen binding proteins comprising a first antigen binding protein, a variant or a binding fragment thereof, that binds to EpCAM (epithelial cell adhesion molecule) and a second antigen binding protein, a variant or a binding fragment thereof, that binds to an immune cell marker, wherein a first antigen binding protein, a variant or a binding fragment thereof binding to EpCAM comprises a heavy chain variable region and / or a light chain variable region comprising a sequence as disclosed herein. Also disclosed are methods of producing / producing the cells as disclosed herein and methods of treatment employing the cells as disclosed herein.